LFB-S.A.
On December 20 th , a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4 th , 2017.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171221005345/en/
Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th , following Christian BÉCHON and Denis SOUBEYRAN’s departures.
A graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy, Denis DELVAL has a deep understanding of the pharmaceutical industry. He has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. Denis DELVAL lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank.
“I am proud to be appointed as CEO of LFB Group and to work for this company operating in a strategic sector. LFB produces therapeutics that are essential for the lives of thousands of patients, particularly in the rare disease field. I am fully aware of the challenges ahead and look forward to unleashing energies to make this pharmaceutical company successful in France and internationally.”
* The Official Journal of the French Republic.
About LFB Group
LFB is a biopharmaceutical group
that develops, manufactures, and markets medicinal products derived from
living matter for the treatment of serious and often rare diseases in
several major therapeutic fields, including Hemostasis, Immunology and
Intensive Care. LFB is the leading manufacturer of plasma-derived
medicinal products in France and 7
th
worldwide,
and is also among the leading European companies for the development of
new-generation medicinal products or treatments based on
biotechnologies. Through its constant research efforts, the LFB group
implements a growth strategy to expand its activities on international
markets. Today, LFB currently markets its products in almost 60
countries around the world with a global turnover of €518.9 million in
2016. LFB group employs more than 2300 people worldwide.
www.groupe-lfb.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005345/en/
Contact:
LFB SA
Sandrine Charrières, Tel : +33-(0)1-6982-7280
Executive
VP Corporate Communications
charrieres@lfb.fr
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AmTrust Strengthens Its Position in Türkiye After Successful Year of Growth19.5.2025 10:00:00 CEST | Press release
AmTrust International, a global specialty insurer and reinsurer, has announced significant progress in its Turkish operations following the successful opening of its office in Istanbul last year. This growth aligns with AmTrust’s ongoing strategic goal of enhancing underwriting profitability and expanding its geographical footprint in the credit protection and affinity sector. Over the past year, AmTrust’s team in Türkiye, led by General Manager Erdinc Karayazlik, has successfully strengthened the company’s foothold in the specialty market. With 20 years of experience in senior insurance distribution roles across Türkiye, the Middle East, Europe, and Africa, and supported by his experienced team, Karayazlik has been instrumental in driving initiatives that have further developed AmTrust’s offerings, including mortgages, credit protection and rent guarantees while working across geographies. “I’m thrilled with the progress we’ve made since our establishment in Türkiye. Our focus on the
GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions19.5.2025 09:29:00 CEST | Press release
GIGABYTE, a global leader in IT and AI infrastructure, is set to showcase its full-stack AI solutions at COMPUTEX 2025 from May 20–23, under the theme “Omnipresence of Computing: AI Forward.” With end-to-end innovations spanning cloud, data center, edge, and application, GIGABYTE is redefining what computing can achieve in the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514218509/en/ GIGABYTE at COMPUTEX 2025: Accelerating the AI Future With Total Infrastructure and Computing Solutions Total Data Center Solutions: From Hardware to Cluster Management At the heart of the showcase is GIGAPOD, GIGABYTE’s high-density, rack-scale infrastructure for AI workloads. Integrated with GPM, GIGABYTE’s in-house management platform, the solution enables unified orchestration of resources, from node to rack to cluster. This powerful combination supports rapid deployment, workload optimization, and real-time system monitoring—f
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 08:00:00 CEST | Press release
New GUINNESS WORLD RECORDS Title for Most Accurate Value of Pi - 300 Trillion Digits Calculated Using KIOXIA NVMe™ SSDs Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 08:00:00 CEST | Press release
Businesses using NetApp AIPod can accelerate AI agents and speed up retrieval of relevant information NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data est
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom